$RCPT..Between May 16 and May 19, additional TOUCHSTONE analyses will be disclosed at Digestive Disease Week in Washington DC.
Receptos focuses on developing therapies for immune disorders. The company is developing RPC1063 for IBD, or inflammatory bowel disease, which is comprised of two autoimmune diseases; ulcerative colitis and Crohn’s disease. In late 2014, Receptos announced that the TOUCHSTONE Phase 2 trial of the drug met its endpoint in ulcerative colitis.
Wedbush currently has an Outperform rating on Receptos with a $201 price target.
Sheff's Station...All Aboard...Sign Up Here!
